Unlock instant, AI-driven research and patent intelligence for your innovation.

Model for predicting curative effect of csDMARDs for treating rheumatoid arthritis and establishment method thereof

A technology for arthritis and rheumatoid, applied in the field of medicine, can solve the problems of unreported and predicting the prognosis of patients, and achieve the effects of reducing misjudgment, improving the quality of life, and avoiding disability

Pending Publication Date: 2022-08-05
SHANDONG UNIV QILU HOSPITAL
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The above cytokines can be accurately measured in peripheral blood levels, but there is no single inflammatory factor index that can be used to predict the prognosis of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Model for predicting curative effect of csDMARDs for treating rheumatoid arthritis and establishment method thereof
  • Model for predicting curative effect of csDMARDs for treating rheumatoid arthritis and establishment method thereof
  • Model for predicting curative effect of csDMARDs for treating rheumatoid arthritis and establishment method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Example 1 Construction of a prediction model for the efficacy of csDMARDs in the treatment of rheumatoid arthritis

[0051] All patients were evaluated for disease activity by ACR 1987 criteria and ACR / EULAR 2010 criteria. 184 patients with moderate-to-severe disease activity rheumatoid arthritis who received traditional csDMARDs were randomly divided into developmental groups using R software in a ratio of 7:3. cohort (129 cases) and validation cohort (55 cases).

[0052] The basic information of the patient was collected in detail, including age, gender, family history, etc. Plasma was collected from the patients, and the levels of TNF-α, IL-6, Gal-9 and VEGF were detected. All enrolled patients were given methotrexate (MTX), tacrolimus (FK506), iguratimod (T-614), hydroxychloroquine (HCQ), Treatment with one or more of the csDMARDs, such as leflunomide (LEF). Non-steroidal anti-inflammatory drugs (NSAIDs) and hormonal drugs are used in combination if necessary acc...

Embodiment 2

[0061] Verification and Comparison of the Model of Example 2

[0062] The discriminative degree of the model was evaluated by the degree of discrimination and the area under the ROC curve. Calculated C-Index 0.73 (95%CI: 0.56-0.90) for this nomogram development cohort. C-Index of the validation cohort 0.70 (95% CI: 0.53-0.88). This shows that our model has better discrimination. The time-dependent ROC curve analysis showed that the AUC of the development cohort to predict the nomograms of 3 months, 6 months and 12 months were 0.76, 0.82 and 0.73 ( Image 6 ). The nomogram had significant discriminatory power in predicting remission, and higher nomogram scores indicated that patients were more likely to achieve remission earlier. The calculated AUCs of the development cohort nomograms were all greater than 0.5 with the change of follow-up time, which showed that our prediction model did not show a decrease in stability over time ( Figure 7 ).

[0063] We assessed the acc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicines, in particular to a model for predicting the curative effect of csDMARDs in treating rheumatoid arthritis and an establishment method of the model. By incorporating mutually independent indexes in three aspects, namely, illness state activity, inflammation level and immune disorder, the method is simple, intuitive and easy to detect, popularize and apply. A clinician can carry out accurate individualized evaluation, curative effect prediction and treatment benefit at the beginning of receiving csDMARDs on a rheumatoid arthritis patient; the method has an important hygienic economic value for planning whether a patient with rheumatoid arthritis is subjected to persistent csDMARDs treatment in advance or needs to replace a scheme as soon as possible, and helps the patient to obtain better life quality as soon as possible.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a model for predicting the curative effect of csDMARDs in treating rheumatoid arthritis and a method for establishing the same. Background technique [0002] Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovial hyperplasia and pannus infiltration. Various inflammatory cytokines are abundant in RA synovial tissue and peripheral blood. Inflammation of the synovium persists. If the persistent immune inflammatory response in active RA is not effectively controlled, the patient's condition will continue to progress, and the hyperplastic synovium destroys the articular ligaments and erodes the bone tissue, causing irreversible dysfunction and disability; Hematological diseases seriously affect the life expectancy and quality of life of patients. Early and timely and powerful treatment strategies can control most patients to achieve clinical remission (remission) or low...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G16H50/30G16H20/10G06Q10/04
CPCG16H50/30G16H20/10G06Q10/04
Inventor 舒强孙志坚宋立军刘新雷王飞英孙姣隋雅梦
Owner SHANDONG UNIV QILU HOSPITAL